Recent settlements between the U.S. Federal Trade Commission (FTC) and six CBD operators underscore the latest attempt to curtail long-running mislabeling concerns.
This latest round of enforcement actions was triggered by specific concerns with the manner in which many CBD products were administered.
No clinical trials exist to corroborate such claims.
FOR A WEEKLY DOSE OF THE FRESH TOAST
Hand selected from our editors with all the latest news and entertainment with a side of cannabis.